Blocking CGRP in migraine patients - a review of pros and cons

Marie Deen, Edvige Correnti, Katharina Kamm, Tim Kelderman, Laura Papetti, Eloisa Rubio-Beltrán, Simone Vigneri, Lars Edvinsson, Antoinette Maassen Van Den Brink, European Headache Federation School of Advanced Studies (EHF-SAS), Marie Deen, Edvige Correnti, Katharina Kamm, Tim Kelderman, Laura Papetti, Eloisa Rubio-Beltrán, Simone Vigneri, Lars Edvinsson, Antoinette Maassen Van Den Brink, European Headache Federation School of Advanced Studies (EHF-SAS)

Abstract

Migraine is the most prevalent neurological disorder worldwide and it has immense socioeconomic impact. Currently, preventative treatment options for migraine include drugs developed for diseases other than migraine such as hypertension, depression and epilepsy. During the last decade, however, blocking calcitonin gene-related peptide (CGRP) has emerged as a possible mechanism for prevention of migraine attacks. CGRP has been shown to be released during migraine attacks and it may play a causative role in induction of migraine attacks. Here, we review the pros and cons of blocking CGRP in migraine patients. To date, two different classes of drugs blocking CGRP have been developed: small molecule CGRP receptor antagonists (gepants), and monoclonal antibodies, targeting either CGRP or the CGRP receptor. Several trials have been conducted to test the efficacy and safety of these drugs. In general, a superior efficacy compared to placebo has been shown, especially with regards to the antibodies. In addition, the efficacy is in line with other currently used prophylactic treatments. The drugs have also been well tolerated, except for some of the gepants, which induced a transient increase in transaminases. Thus, blocking CGRP in migraine patients is seemingly both efficient and well tolerated. However, CGRP and its receptor are abundantly present in both the vasculature, and in the peripheral and central nervous system, and are involved in several physiological processes. Therefore, blocking CGRP may pose a risk in subjects with comorbidities such as cardiovascular diseases. In addition, long-term effects are still unknown. Evidence from animal studies suggests that blocking CGRP may induce constipation, affect the homeostatic functions of the pituitary hormones or attenuate wound healing. However, these effects have so far not been reported in human studies. In conclusion, this review suggests that, based on current knowledge, the pros of blocking CGRP in migraine patients exceeds the cons.

Keywords: Acute treatment; Cgrp; Cgrp receptor; Gepants; Migraine; Prophylactic treatment.

Conflict of interest statement

Ethics approval and consent to participate

Not applicable

Consent for publication

Not applicable

Competing interests

AMvdB received research grants from Amgen/Novartis. LE has given talks and received grant for preclinical studies sponsored by Novartis and TEVA.

All other authors declare no conflicts of interest.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Efficacy of gepants in the acute treatment of migraine. Bars indicated with * represents statistically significant values compared to placebo (p < 0.05)
Fig. 2
Fig. 2
Efficacy of monoclonal antibodies in the preventive treatment of migraine. Bars indicated with * represents statistically significant values compared to placebo (p < 0.05). (1) had change in mean monthly migraine days from baseline to weeks 5–8 as the primary endpoint. All other studies had change in monthly migraine days from baseline to weeks 9–12 of the 12-week double-blind treatment phase as the primary endpoint. In (1) the drug/placebo was administered intravenously. In all other studies, the drug/placebo were given subcutaneously. (2) is on chronic migraine patients. All other studies are on episodic migraine patients
Fig. 3
Fig. 3
Possible side effects after long-term exposure to CGRP (receptor)-antibodies. An overview of the organ systems where CGRP and the receptor are present and possible side effects that could be caused by the non-selective blockade of α- and β-CGRP with the CGRP (receptor)-antibodies

References

    1. Edvinsson L. Functional role of perivascular peptides in the control of cerebral circulation. Trends Neurosci. 1985;2:2–7.
    1. Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol. 1993;33:48–56. doi: 10.1002/ana.410330109.
    1. Goadsby PJ, Edvinsson L. Peripheral and central Trigeminovascular activation in cat is blocked by the serotonin (5HT)-I D receptor agonist 311C90. Headache J Head Face Pain. 1994;34:394–399. doi: 10.1111/j.1526-4610.1994.hed3407394.x.
    1. Lassen LH, Haderslev PA, Jacobsen VB, et al. CGRP may play a causative role in migraine. Cephalalgia. 2002;22:54–61. doi: 10.1046/j.1468-2982.2002.00310.x.
    1. Uddman R, Edvinsson L, Ekman R, et al. Innervation of the feline cerebral vasculature by nerve fibers containing calcitonin gene-related peptide: trigeminal origin and co-existence with substance P. Neurosci Lett. 1985;62:131–136. doi: 10.1016/0304-3940(85)90296-4.
    1. Edvinsson L. CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment. Br J Clin Pharmacol. 2015;80:193–199. doi: 10.1111/bcp.12618.
    1. Eftekhari S, Warfvinge K, Blixt FW, Edvinsson L. Differentiation of nerve fibers storing CGRP and CGRP receptors in the peripheral trigeminovascular system. J Pain. 2013;14:1289–1303. doi: 10.1016/j.jpain.2013.03.010.
    1. Eftekhari S, Edvinsson L. Possible sites of action of the new calcitonin gene-related peptide receptor antagonists. Ther Adv Neurol Disord. 2010;3:369–378. doi: 10.1177/1756285610388343.
    1. MaassenVanDenBrink A, Meijer J, Villalón CM, Ferrari MD. Wiping out CGRP: potential cardiovascular risks. Trends Pharmacol Sci. 2016;37:779–788. doi: 10.1016/j.tips.2016.06.002.
    1. Schou WS, Ashina S, Amin FM, et al. Calcitonin gene-related peptide and pain: a systematic review. J Headache Pain. 2017;18:34. doi: 10.1186/s10194-017-0741-2.
    1. Edvinsson L, Linde M. New drugs in migraine treatment and prophylaxis: Telcagepant and topiramate. Lancet. 2010;376:645–655. doi: 10.1016/S0140-6736(10)60323-6.
    1. Russell FA, King R, Smillie S-J, et al. Calcitonin gene-related peptide: physiology and Pathophysiology. Physiol Rev. 2014;94:1099–1142. doi: 10.1152/physrev.00034.2013.
    1. Doods H, Hallermayer G, Wu D, et al. Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist. Br J Pharmacol. 2000;129:420–423. doi: 10.1038/sj.bjp.0703110.
    1. Vécsei L, Szok D, Csáti A, Tajti J. CGRP antagonists and antibodies for the treatment of migraine. Expert Opin Investig Drugs. 2015;24:31–41. doi: 10.1517/13543784.2015.960921.
    1. Bigal ME, Walter S, Rapoport AM. Calcitonin gene-related peptide (CGRP) and migraine current understanding and state of development. Headache. 2013;53:1230–1244. doi: 10.1111/head.12179.
    1. Juhl L, Edvinsson L, Olesen J, Jansen-Olesen I. Effect of two novel CGRP-binding compounds in a closed cranial window rat model. Eur J Pharmacol. 2007;567:117–124. doi: 10.1016/j.ejphar.2007.04.004.
    1. Edvinsson L, Nilsson E, Jansen-Olesen I. Inhibitory effect of BIBN4096BS, CGRP(8-37), a CGRP antibody and an RNA-Spiegelmer on CGRP induced vasodilatation in the perfused and non-perfused rat middle cerebral artery. BrJPharmacol. 2007;150:633–640.
    1. Olesen J, Diener H, Husstedt IW, et al (2004) Calcitonin gene–related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. Society 1104–1110
    1. Connor KM, Aurora SK, Loeys T, et al. Long-term tolerability of telcagepant for acute treatment of migraine in a randomized trial. Headache. 2011;51:73–84. doi: 10.1111/j.1526-4610.2010.01799.x.
    1. Connor KM, Shapiro RE, Diener H-C, et al. Randomized, controlled trial of telcagepant for the acute treatment of migraine. Neurology. 2009;73:970–977. doi: 10.1212/WNL.0b013e3181b87942.
    1. Diener H-C, Barbanti P, Dahlöf C, et al. BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study. Cephalalgia. 2011;31:573–584. doi: 10.1177/0333102410388435.
    1. Hewitt DJ, Aurora SK, Dodick DW, et al. Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine. Cephalalgia. 2011;31:712–722. doi: 10.1177/0333102411398399.
    1. Hewitt DJ, Martin V, Lipton RB, et al. Randomized controlled study of telcagepant plus ibuprofen or acetaminophen in migraine. Headache. 2011;51:533–543. doi: 10.1111/j.1526-4610.2011.01860.x.
    1. Ho AP, Dahlöf CG, Silberstein SD, et al. Randomized, controlled trial of telcagepant over four migraine attacks. Cephalalgia. 2010;30:1443–1457. doi: 10.1177/0333102410370878.
    1. Ho TW, Connor KM, Zhang Y, et al. Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention. Neurology. 2014;83:958–966. doi: 10.1212/WNL.0000000000000771.
    1. Ho TW, Ferrari MD, Dodick DW, et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet. 2008;372:2115–2123. doi: 10.1016/S0140-6736(08)61626-8.
    1. Ho TW, Ho AP, Chaitman BR, et al. Randomized, controlled study of telcagepant in patients with migraine and coronary artery disease. Headache. 2012;52:224–235. doi: 10.1111/j.1526-4610.2011.02052.x.
    1. Ho TW, Ho AP, Ge Y (Joy), et al (2016) Randomized controlled trial of the CGRP receptor antagonist telcagepant for prevention of headache in women with perimenstrual migraine. Cephalalgia 36:148–161. doi: 10.1177/0333102415584308
    1. Ho TW, Mannix LK, Fan X, et al. Randomized controlled trial of an oral CGRP receptor antagonist, MK-3207, in the acute treatment of migraine. Neurology. 2008;70:1304–1312. doi: 10.1212/01.WNL.0000286940.29755.61.
    1. Marcus R, Goadsby PJ, Dodick D, et al. BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial. Cephalalgia. 2014;34:114–125. doi: 10.1177/0333102413500727.
    1. Sun H, Dodick DW, Silberstein S, et al. Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2016;15:382–390. doi: 10.1016/S1474-4422(16)00019-3.
    1. Tepper S, Ashina M, Reuter U, et al (2017) Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. doi: 10.1016/S1474-4422(17)30083-2
    1. Voss T, Lipton RB, Dodick DW, et al. A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine. Cephalalgia. 2016;36:887–898. doi: 10.1177/0333102416653233.
    1. Dodick DW, Goadsby PJ, Silberstein SD, et al. Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurol. 2014;13:1100–1107. doi: 10.1016/S1474-4422(14)70209-1.
    1. Dodick DW, Goadsby PJ, Spierings ELH, et al. Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Neurol. 2014;13:885–892. doi: 10.1016/S1474-4422(14)70128-0.
    1. Bigal ME, Dodick DW, Rapoport AM, et al. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol. 2015;14:1081–1090. doi: 10.1016/S1474-4422(15)00249-5.
    1. Bigal ME, Edvinsson L, Rapoport AM, et al. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol. 2015;14:1091–1100. doi: 10.1016/S1474-4422(15)00245-8.
    1. D’Amico D, Tepper SJ. Prophylaxis of migraine: General principles and patient acceptance. Neuropsychiatr Dis Treat. 2008;4:1155–1167. doi: 10.2147/NDT.S3497.
    1. Silberstein SD, Holland S, Freitag F, et al. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults. Neurology. 2012;78:1337–45. doi: 10.1212/WNL.0b013e3182535d20.
    1. Lilly’s Galcanezumab Significantly Reduces Number of Migraine Headache Days for Patients with Migraine: New Results Presented at AHS (NYSE:LLY). . Accessed 21 Aug 2017
    1. Alder BioPharmaceuticals Announces Positive Eptinezumab Phase 3 Results for Prevention of Frequent Episodic Migraine (NASDAQ:ALDR). . Accessed 21 Aug 2017
    1. Teva’s Fremanezumab Meets all Primary and Secondary Endpoints Across Both Monthly and Quarterly Dosing Regimens in Phase III Study in Episodic Migraine Prevention. . Accessed 21 Aug 2017
    1. Novartis announces Phase III study shows AMG 334 significantly reduces monthly migraine days in people with episodic migraine | Novartis. . Accessed 21 Aug 2017
    1. Brandes J, Saper J, Diamond M, et al. Topiramate for migraine prevention: a randomized controlled trial. JAMA. 2004;291:965–973. doi: 10.1001/jama.291.8.965.
    1. Diener H-C, Tfelt-Hansen P, Dahlöf C, et al. Topiramate in migraine prophylaxis results from a placebo-controlled trial with propranolol as an active control. J Neurol. 2004;251:943–950. doi: 10.1007/s00415-004-0464-6.
    1. Silberstein SD, Standnes B, Kangasneimi P, et al (2004) Topiramate in migraine prevention. Arch Neurol 61:490–495. doi:10.1001/archneur.61.4.490
    1. Silberstein SD, Lipton RB, Dodick DW, et al. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache. 2007;47:170–180. doi: 10.1111/j.1526-4610.2006.00684.x.
    1. Diener HC, Bussone G, Van Oene JC, et al. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia. 2007;27:814–823. doi: 10.1111/j.1468-2982.2007.01326.x.
    1. Lilly Announces Positive Results for Three Phase 3 Studies of Galcanezumab for the Prevention of Episodic and Chronic Migraine (NYSE:LLY). . Accessed 21 Aug 2017.
    1. Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008;84:548–558. doi: 10.1038/clpt.2008.170.
    1. Bigal ME, Walter S, Rapoport AM. Therapeutic antibodies against CGRP or its receptor. Br J Clin Pharmacol. 2015;79:886–895. doi: 10.1111/bcp.12591.
    1. Iyengar S, Ossipov MH, Johnson KW. The role of CGRP in peripheral and central pain mechanisms including migraine. Pain. 2016;158:543–559. doi: 10.1097/j.pain.0000000000000831.
    1. Sur C, Hargreaves RJ, Bell IM, et al. CSF levels and binding pattern of novel CGRP receptor antagonists in rhesus monkey and human central nervous system: toward the development of a PET tracer. Cephalalgia. 2009;29:136–137.
    1. Uddman R, Edvinsson L, Ekblad E et al (1986) Calcitonin gene-related peptide (CGRP): perivascular distribution and vasodilatory effects. Regul Pept 15:1–23. doi:10.1016/0167-0115(86)90071-6
    1. Wimalawansa J, MacIntyre I (1988) Calcitonin gene-related peptide and its specific binding sites in the cardiovascular system of rat. Int J Cardiol 20:29–37
    1. Opgaard OS, Gulbenkian S, Bergdahl A, et al. Innervation of human epicardial coronary veins: immunohistochemistry and vasomotility. Cardiovasc Res. 1995;29:463–468. doi: 10.1016/S0008-6363(96)88520-8.
    1. Lindstedt IH, Edvinsson M-L, Edvinsson L. Reduced responsiveness of cutaneous microcirculation in essential hypertension--a pilot study. Blood Press. 2006;15:275–280. doi: 10.1080/08037050600996586.
    1. McCulloch J, Uddman R, Kingman TA, Edvinsson L. Calcitonin gene-related peptide: functional role in cerebrovascular regulation. Proc Natl Acad Sci U S A. 1986;83:5731–5735. doi: 10.1073/pnas.83.15.5731.
    1. Edvinsson L, Uddman R, Mulder H. Calcitonin gene-related peptide and nitric oxide in the trigeminal ganglion: cerebral vasodilation from trigeminal nerve stimulation involves mainly calcitonin gene-related peptide. J Aut Nerv Syst. 1998;70:15–22. doi: 10.1016/S0165-1838(98)00033-2.
    1. Keith IM, Tjen AL, Kraiczi H, Ekman R. Three-week neonatal hypoxia reduces blood CGRP and causes persistent pulmonary hypertension in rats. AmJPhysiolHeart CircPhysiol. 2000;279:H1571–H1578.
    1. Sacco S, Kurth T. Migraine and the risk for stroke and cardiovascular disease. Curr Cardiol Rep. 2014;16:1–7. doi: 10.1007/s11886-014-0524-1.
    1. Kurth T, Winter AC, Eliassen AH, et al. Migraine and risk of cardiovascular disease in women: prospective cohort study. BMJ. 2016;253:i2610. doi: 10.1136/bmj.i2610.
    1. Salmona M, Damaj Mi, Marubio Lm, et al (2001) Altered neuroadaptation in opiate dependence and neurogenic inflammatory nociception in alpha CGRP-deficient mice. Nat Neurosci 4:357–358. doi: 10.1100/tsw.2001.439
    1. Zhang L, Hoff AO, Wimalawansa SJ, et al. Arthritic calcitonin/α calcitonin gene-related peptide knockout mice have reduced nociceptive hypersensitivity. Pain. 2001;89:265–273. doi: 10.1016/S0304-3959(00)00378-X.
    1. Benschop RJ, Collins EC, Darling RJ, et al. Development of a novel antibody to calcitonin gene-related peptide for the treatment of osteoarthritis-related pain. Osteoarthr Cartil. 2014;22:578–585. doi: 10.1016/j.joca.2014.01.009.
    1. Khalil Z, Helme R. Sensory peptides as Neuromodulators of wound healing in aged rats. J Gerontol Ser A Biol Sci Med Sci. 1996;51A:B354–B361. doi: 10.1093/gerona/51A.5.B354.
    1. Roggenkamp D, Köpnick S, Stäb F, et al. Epidermal nerve fibers modulate Keratinocyte growth via Neuropeptide signaling in an innervated skin model. J Invest Dermatol. 2013;133:1620–1628. doi: 10.1038/jid.2012.464.
    1. Mishima T, Ito Y, Hosono K, et al. Calcitonin gene-related peptide facilitates revascularization during hindlimb ischemia in mice. Am J Physiol Circ Physiol. 2011;300:H431–H439. doi: 10.1152/ajpheart.00466.2010.
    1. Zhang X, Zhuang J, Wu H, et al. Inhibitory effects of Calcitonin gene-related peptides on experimental vein graft disease. Ann Thorac Surg. 2010;90:117–123. doi: 10.1016/j.athoracsur.2010.03.063.
    1. Mulderry PK, M A G, R a S, et al. Differential expression of alpha-CGRP and beta-CGRP by primary sensory neurons and enteric autonomic neurons of the rat. Neuroscience. 1988;25:195–205. doi: 10.1016/0306-4522(88)90018-8.
    1. STERNINI C (1992) Enteric and visceral afferent CGRP neurons: targets of Innervation and differential expression patterns. Ann N Y Acad Sci 657:170–186. doi: 10.1111/j.1749-6632.1992.tb22766.x
    1. Peskar BM, Wong HC, Walsh JH, Holzer P. A monoclonal antibody to calcitonin gene-related peptide abolishes capsaicin-induced gastroprotection. Eur J Pharmacol. 1993;250:201–203. doi: 10.1016/0014-2999(93)90645-X.
    1. Reinshagen M, Flämig G, Ernst S, et al. Calcitonin gene-related peptide mediates the protective effect of sensory nerves in a model of colonic injury. J Pharmacol Exp Ther. 1998;286:657–661.
    1. Bartho L, Koczan G, Maggi CA. Studies on the mechanism of the contractile action of rat calcitonin gene-related peptide and of capsaicin on the guinea-pig lleum: effect of hCGRP (8-37) and CGRP tachyphylaxis. Neuropeptides. 1993;25:325–329. doi: 10.1016/0143-4179(93)90051-B.
    1. Ohno T, Hattori Y, Komine R, et al. Roles of Calcitonin gene-related peptide in maintenance of gastric mucosal integrity and in enhancement of ulcer healing and angiogenesis. Gastroenterology. 2008;134:215–225. doi: 10.1053/j.gastro.2007.10.001.
    1. Schankin CJ, Maniyar FH, Seo Y, et al. Ictal lack of binding to brain parenchyma suggests integrity of the blood-brain barrier for 11C-dihydroergotamine during glyceryl trinitrate-induced migraine. Brain. 2016;139:1994–2001. doi: 10.1093/brain/aww096.
    1. Hougaard A, Amin FM, Christensen CE, et al. Increased brainstem perfusion, but no blood-brain barrier disruption, during attacks of migraine with aura. Brain. 2017;140:1–10. doi: 10.1093/brain/awx089.
    1. Eftekhari S, Salvatore CA, Johansson S, et al. Localization of CGRP, CGRP receptor, PACAP and glutamate in trigeminal ganglion. Relation to the blood-brain barrier. Brain Res. 2015;1600:93–109. doi: 10.1016/j.brainres.2014.11.031.
    1. Wimalawansa SJ, El-Kholy AA. Comparitive study of distribution and biochemical characterization of brain calcitonin gene-related peptide receptors in five different species. Neuroscience. 1993;54:513–519. doi: 10.1016/0306-4522(93)90270-P.
    1. Mitsikostas DD, Reuter U. Calcitonin gene-related peptide monoclonal antibodies for migraine prevention : comparisons across randomized controlled studies. Curr Opin Neurol. 2017;30:272–280. doi: 10.1097/WCO.0000000000000438.
    1. Hepp Z, Dodick DW, Varon SF, et al. Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia. 2015;35:478–488. doi: 10.1177/0333102414547138.
    1. Hepp Z, Bloudek LM, Varon SF. Systematic review of migraine prophylaxis adherence and persistence. J Manag Care Pharm. 2014;20:22–33.
    1. Zhou H, Mascelli MA. Mechanisms of monoclonal antibody–drug interactions. Annu Rev Pharmacol Toxicol. 2011;51:359–372. doi: 10.1146/annurev-pharmtox-010510-100510.
    1. Gangula PRR, Wimalawansa SJ, Yallampalli C. Sex steroid hormones enhance Hypotensive effects of Calcitonin gene-related peptide in aged female rats. Biol Reprod. 2002;67:1881–1887. doi: 10.1095/biolreprod.102.007682.
    1. Walker CS, Eftekhari S, Bower RL, et al. A second trigeminal CGRP receptor: function and expression of the AMY1 receptor. Ann Clin Transl Neurol. 2015;2:595–608. doi: 10.1002/acn3.197.
    1. Haanes KA, Chan KY, MaassenVanDenBrink A. Comment on “a second trigeminal CGRP receptor: function and expression of the AMY1 receptor.”. Ann Clin Transl Neurol. 2016;3:307–308. doi: 10.1002/acn3.286.
    1. Estemalik E, Tepper S. Preventive treatment in migraine and the new US guidelines. Neuropsychiatr Dis Treat. 2013;9:709–720. doi: 10.2147/NDT.S33769.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel